Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal
Executive Summary
Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.
You may also be interested in...
Pierre Fabre Continues Oncology R&D Push
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
Pfizer's Dolsten On Finding Ways To “Accelerate External Science”
Worldwide President of R&D Mikael Dolsten talked to Scrip about Pfizer's busy business development track record and the company's ambition to maintain its leadership in breast cancer.
Stockwatch: Coronavirus Distorts The Shape Of Pfizer Results
Pfizer’s results may have heralded a third-quarter stabilization of pandemic-related effects had the costs and expectations for its vaccine not hijacked sentiment.